C
Charles A. Dinarello
Researcher at University of Colorado Denver
Publications - 1073
Citations - 152254
Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.
Papers
More filters
Journal Article
Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans.
Eric V. Granowitz,Reuven Porat,James W. Mier,Scott F. Orencole,Gilles Kaplanski,Elizabeth A. Lynch,Ke Ye,Edouard Vannier,Sheldon M. Wolff,Charles A. Dinarello +9 more
TL;DR: It is concluded that endotoxin tolerance is due, in part, to changes in the stimulus-induced cytokine response of circulating CD14+ cells.
Journal ArticleDOI
IL-37 protects against obesity-induced inflammation and insulin resistance
Dov B. Ballak,Janna A. van Diepen,Alexander R. Moschen,H.J. Jansen,Anneke Hijmans,Gert-Jan Groenhof,Floris Leenders,Philip Bufler,Mark V. Boekschoten,Michael Müller,Sander Kersten,Suzhao Li,Soohyun Kim,Hadar Eini,Eli C. Lewis,Leo A. B. Joosten,Herbert Tilg,Mihai G. Netea,Cees J. Tack,Charles A. Dinarello,Rinke Stienstra +20 more
TL;DR: It is shown that IL-1 family member IL-37, recently characterized as an anti-inflammatory cytokine, ameliorates obesity-induced inflammation and insulin resistance in both mice and humans and is suggested as a potential target for the treatment of Obesity-induced insulin resistance and type 2 diabetes.
Journal ArticleDOI
Enhancement of growth of virulent strains of Escherichia coli by interleukin-1
TL;DR: HumanIL-1 may recognize a functional IL-1-like receptor structure on virulent E. coli and may be a virulence factor for bacterial pathogenicity.
Journal ArticleDOI
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
Thomas A Rasmussen,Ole S. Søgaard,Christel R. Brinkmann,Fiona Wightman,Sharon R Lewin,Jesper Melchjorsen,Charles A. Dinarello,Lars Østergaard,Martin Tolstrup +8 more
TL;DR: Panobinostat was significantly more potent than all other HDAC inhibitors and induced virus production even in the very low concentration range 8–31 nM and is now being advanced into clinical testing against latent HIV infection.
Journal ArticleDOI
IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis
Rossana G. Iannitti,Valerio Napolioni,Vasilis Oikonomou,Antonella De Luca,Claudia Galosi,Marilena Pariano,Cristina Massi-Benedetti,Monica Borghi,Matteo Puccetti,Vincenzina Lucidi,Carla Colombo,Ersilia Fiscarelli,Cornelia Lass-Flörl,Fabio Majo,Lisa Cariani,Maria Chiara Russo,Luigi Porcaro,Gabriella Ricciotti,Helmut Ellemunter,Luigi Ratclif,Fernando Maria de Benedictis,Vincenzo Nicola Talesa,Charles A. Dinarello,Frank L. van de Veerdonk,Luigina Romani +24 more
TL;DR: Results indicate that pathogenic NLRP3 activity in CF could be negatively regulated by IL-1Ra and provide a proof-of-concept evidence that inflammasomes are potential targets to limit the pathological consequences of microbial colonization in CF.